key: cord-0717792-etfb05fb authors: Pallanti, Stefano; Grassi, Eleonora; Makris, Nikos; Gasic, Gregory P.; Hollander, Eric title: Neurocovid-19: A Clinical Neuroscience-Based Approach to Reduce SARS-CoV-2 Related Mental Health Sequelae date: 2020-08-15 journal: J Psychiatr Res DOI: 10.1016/j.jpsychires.2020.08.008 sha: 786fd8c5439e152de8476158659e2efa3343fbe8 doc_id: 717792 cord_uid: etfb05fb Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, is a disaster due to not only its psychosocial impact but it also to its direct effects on the brain. The latest evidence suggests it has neuroinvasive mechanisms, in addition to neurological manifestations, and as seen in past pandemics, long-term sequelae are expected. Specific and well-structured interventions are necessary, and that’s why it’s important to ensure a continuity between primary care, emergency medicine, and psychiatry. Evidence shows that 2003 SARS (Severe Acute Respiratory Syndrome) survivors developed persistent psychiatric comorbidities after the infection, in addition to Chronic Fatigue Syndrome. A proper stratification of patients according not only to psychosocial factors but also an inflammatory panel and SARS-Cov-2’s direct effects on the central nervous system (CNS) and the immune system, may improve outcomes. The complexity of COVID-19’s pathology and the impact on the brain requires appropriate screening that has to go beyond the psychosocial impact, taking into account how stress and neuroinflammation affects the brain. This is a call for a clinical multidisciplinary approach to treat and prevent Sars-Cov-2 mental health sequelae. References Respiratory Syndrome -Coronavirus-2 (SARS-CoV-2), can be considered as a unique disaster (from Latin: Astrum + dis, "bad star"), where individuals in a large population are randomly exposed to the trauma of a virus that has direct effects on the Central Nervous System (CNS), and subsequently induces an immunological response 1 . strong binding affinity to the angiotensin-converting enzyme-2(ACE2) to gain entry into cells 2 . This receptor is expressed in lungs, heart, kidneys, testicles, venous endothelial cells and small intestinal enterocytes 3 . ACE2 is also widely expressed in the mouse and human brain although current human evidence is strongest for its expression on endothelial and smooth muscle cells 4 . Moreover, type I interferon IFNs (IFNα), and to a lesser extent Type II IFNs (IFNγ), upregulate ACE2 in airway epithelial cells, and SARS-CoV-2 may be using the IFN response for its benefit 5 . Acute inflammation is part of innate immunity's response to harmful stimuli, and triggers adaptive immunity, whereas excessive or chronic inflammation causes disease. How the virus enters the CNS -In patients diagnosed with viral encephalitis, gene sequencing showed SARS-CoV-2's presence in the cerebrospinal fluid, confirming its neuroinvasive potential 6 . Several hypotheses have been advanced to explain how SARS-CoV-2 enters the CNS: hematogenous dissemination, neuronal retrograde transport and the passage via the nasal cavity across the cribriform plate that supports the olfactory bulb 6 . The virus can be disseminated throughout the body via the bloodstream, and across vascular beds of different organs by disrupting ACE2 bearing endothelial cells 7 . The presence and persistence of human coronaviruses in the brain have been proposed to cause acute and long-term sequelae, whereas their activities in prodromal or asymptomatic phase are still unknown. . Hyperketonemia has also been reported. Interleukin (IL)-6, Tumor Necrosis Factor (TNF)-alpha, IL-8, IL-10, and IL-2R are significantly higher among fatal COVID-19 cases as reported for SARS-CoV-1's infection 10, 11 . Tlymphocytes, expressing ACE2 12 , play a decisive role in maintaining immune homeostasis: lymphopenia and increased neutrophil-lymphocyte ratio have been seen in approximately 80% of SARS-CoV-2's patients 10 . mechanism to the pathoetiology of mood disorders 18 . Another threat to the CNS is represented by inflammatory factors that specifically impact neurodevelopment 19 ; convergent evidence suggests that exposure to the mother to inflammation during pregnancy is associated with the later development of neuropsychiatric disorders in human offspring 20 . During infection, fetal villous tissues secrete a number of inflammatory and immunoregulatory cytokines and chemokines, contributing to their presence at the fetal-maternal interface. SARS-CoV-2 infection during pregnancy and childhood may lead to the manifestation of neurodevelopmental disorders. Individuals exposed to SARS-CoV-2, as well as offspring of exposed mothers, should be assessed for neuropsychiatric, neuroimmune and inflammatory status in longitudinal studies to better understand the pathophysiology, and to allow for early intervention. represents a well-known hazard 21 but the neuro-behavioral sequalae of SARS-CoV-2 may not be detected by the common psychological assessment and the concomitant support may be not enough. To counter the direct and indirect CNS harm inflicted by this virus including stress and inflammation, a continuity between primary care, emergency medicine, inpatient treatment, and psychiatry is needed using clinical assessment at specific phases and stages 22 . Studies suggest that psychotherapy leads to measurable neuroimaging changes associated with functional improvement 23 and psychosocial interventions may be associated with an improvement of beneficial immune system function and a decrease in harmful immune system function, with changes persisting for at least 6 months following treatment 24 As seen in SARS (Severe acute respiratory syndrome) survivors, Ho-Bun Lam and colleagues 25 showed that many SARS survivors developed psychiatric morbidity that persisted at 4 year follow up, and many psychosocial factors (such as being a health care worker at the time of infection, being unemployed after recovery and having perception of social stigmatization) increased the risk of developing psychiatric morbidity. More specifically, only 3.3% of the SARS survivors who participated to the study had a history of psychiatric disorders before contracting SARS; otherwise many patients experienced at least one psychiatric illness after SARS infection (42.5%) and the main diagnoses included posttraumatic stress disorders (54.5%), depression (39%), somatoform pain disorder (36.4%), panic disorder (32.5%) and obsessive-compulsive disorder (15.6%). The study suggests the use of specific instruments and trained personnel to improve diagnostic evaluation and stratification. Even if the long-term outcome of Covid-19 is unknown at this time, patient stratification will allow for assessment of antiinflammatory interventions (such as the use of fluoxetine, fluvoxamine, SSRI and trazodone) and a reduction of stigma associated with mental health sequela of the disorder. Such stratification utilizing an inflammatory panel, may help to tailor appropriate therapeutic and rehabilitative programs. While this was not done for SARS survivors, it is now time to do so for COVID-19 patients. Also, psychosocial support should be an essential part of the patient's overall multidisciplinary medical treatment, and this would also reduce the stigma of mental health treatment. Many individuals subject to lockdowns and social distancing may succumb to loneliness-associated elevated levels of markers for inflammation and an increased sensitivity to negative social experiences 26 . Although SARS-CoV-2 may stress several systems of the body in the process of overcoming the infection including the brain, an individual's response need not be pathological 27 . The net stress experienced by a given individual is not deterministic, but their response defines "subjective vulnerability" and "resilience characteristics" or what is called "post traumatic growth". Where do we go from here? -As of May 21st, there have been more than 5.2 million cases (and 330 thousand J o u r n a l P r e -p r o o f deaths) worldwide resulting from the SARS-CoV-2 pandemic, and an effective vaccine is badly needed. In developed nations with resources that are not available in most of Africa, some parts of Asia, and Latin America, it is time to utilize all of the tools of modern medicine to assess the effects of this devastating virus on the human brain and it's neurological, psychiatric, and psychosocial consequences (such as suicide prevention of COVID 19-infected healthcare workers, economic impact, and grief response in family members). The direct effects of the virus (viremia), immune-mediated response, and sequelae from ACE2 positive cell destruction (blood clots, stroke) need to be considered. Beyond testing for viral RNA sequences or antibodies, we should collect samples and carry out complete molecular (and syndromic) testing and there needs to be a coordinated response by the different branches of medicine. "After 40 years, psychiatry is becoming more mindless than brainless, perhaps digital phenotyping will help the pendulum swing back toward a fresh look at behavior, cognition, and mood" 28 . There is no better time than now to head Insel's advice. SP developed the idea, and all authors made a substantial contribution to the development and writing of this article. SP, acting as corresponding author, had the final responsibility for the decision to submit for publication. We declare no competing interests. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Angiotensin-converting enzyme 2 in the brain: properties and future directions SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms Endothelial cell infection and endotheliitis in COVID-19 Neurologic Manifestations of Hospitalized Patients with Coronavirus SARS-CoV-2 can induce brain and spine demyelinating lesions The trinity of COVID-19: immunity, inflammation and intervention Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study SARS-CoV-2 infects T lymphocytes through its spike proteinmediated membrane fusion Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Science Epidemiology, virology, and clinical features of severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2 Coronavirus Disease-19) Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 Hemorrhagic PosteriorReversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study Maternal Inflammation and Neurodevelopmental Programming: A Review of Preclinical Outcomes and Implications for Translational Psychiatry The clinical process in psychiatry: a clinimetric approach The effects of psychotherapy on Page 5 of 6brain function: a systematic and critical review Psychosocial interventions and immune system function: a systematic review and meta-analysis of randomized clinical trials Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up Inflammation affects social experience: implications for mental health Target article: posttraumatic growth: conceptual foundations and empirical evidence Technology for a New Science of Behavior